

Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

253/LG/SE/NOV/2019/GBSL

14th November 2019

To
The Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

To
The Manager
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code : 509079

Symbol : GUFICBIO

Dear Sirs,

Sub: Seeking extension of time for approval of Standalone Financial Results for the quarter and half year ended September 30, 2019

Pursuant to the provisions of Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance our letter dated November 07, 2019 regarding intimation of Board Meeting to be held on November 14, 2019 for considering the un-audited financial results of the Company for the quarter and year ended 30th September, 2019 ('the said results'), we hereby inform you that the said results could not be finalized today on account of the following grounds:

- As informed earlier, Mr. Indrajit Mukherjee was appointed as an Interim Resolution Professional ('IRP') by the Hon'ble National Company Law Tribunal, Mumbai bench ("NCLT") on account of the petition filed by one of the Operational Creditors of the Company viz. Scorpion Express Private Limited.
- Further, the said matter was settled with the Creditor and accordingly an application for withdrawal of the petition was filed with the NCLT. However, the said matter has not been heard yet by the NCLT and the decision for the same is awaited.
- Further, we would like to inform that the said results are prepared and finalized from the Company's side, however, pursuant to the provisions of the Insolvency and Bankruptcy Code, 2016, the IRP is required to approve the same. Considering the limited time available with the IRP since his appointment, he needs time to get acquainted with the accounts of the Company. Hence, the same cannot be submitted to the Exchanges or published.

The said results shall be considered and approved by the IRP or the Board of Directors of the Company, as the case may be, at the earliest and shall be submitted and published in accordance with the prescribed provisions of SEBI (Listing Obligations and Disclosure Requirements)




Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

Regulations, 2015. In view of the above, we also request the Stock Exchanges not to initiate any action against the Company for not submitting the said results within prescribed timeline.

Further, the trading window in respect of dealing in the Equity Shares of the Company for all the Directors and designated (specified) employees of the Company, shall continue to remain closed until 48 hours after declaration of the Financial Results of the Company for the Quarter and half year ended September 30, 2019

The aforesaid is being informed with the approval of the IRP.

We request you to take the above on record.

Thanking You,

Yours truly,

For Gufic Biosciences Limited



Ami Shah

Company Secretary & Compliance Officer

Membership No. A39579

